[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582351":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":45,"locations":54,"responsibleParty":71,"collaborators":74,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":18,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":18,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":18,"overallStatus":56,"whyStopped":18,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Hospital Universiti Sains Malaysia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Meal replacement therapy .",[13],"Other: Meal replacement therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Dietary consultation.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Meal replacement therapy","A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving",[9],[25],"Contro Eazy Now.",[27,31,35,37,40,43],{"name":28,"affiliation":29,"role":30},"Nani Draman, Masters","Professor","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":33,"role":34},"Siti suhaila, Masters","DR","STUDY_CHAIR",{"name":36,"affiliation":33,"role":34},"NG Ying ying, Masters",{"name":38,"affiliation":39,"role":34},"Najib Majdi, PHD","Prof",{"name":41,"affiliation":42,"role":34},"Khairun Nisah Ibrahim, Masters","Miss",{"name":44,"affiliation":33,"role":34},"Kanmani Kumaran, MD",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":18,"email":50},"kanmani kumaran, MD","CONTACT","+60135125136","kanmanikumaran@yahoo.com",{"name":28,"role":48,"phone":52,"phoneExt":18,"email":53},"+601115184421","drnani@usm.my",[55],{"facility":5,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Kubang Kerian","Kelantan","16150","Malaysia","MY",{"type":63,"coordinates":64},"Point",[65,66],102.27938,6.09123,{"lat":66,"lon":65},[69,70],{"name":47,"role":48,"phone":49,"phoneExt":18,"email":50},{"name":28,"role":48,"phone":52,"phoneExt":18,"email":53},{"type":30,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Kanmani Kumaran","Dr",[75],{"name":76,"class":77},"Ethos Healthcare Sdn Bhd company","UNKNOWN","100582351","effect-of-meal-replacement-therapy-on-glucose-control-and-metabolic-parameters-in-patients-with-uncontrolled-diabetes-100582351",false,"NCT06862180","Effect of Meal Replacement Therapy on Glucose Control and Metabolic Parameters in Patients With Uncontrolled Diabetes","The Effect of Meal Replacement Therapy on Glucose Control and Other Metabolic Parameters in Patients With Uncontrolled Type 2 Diabetes on Oral Hypoglycemic Agents: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients between ≥ 30 to ≤ 65 years old\n2. Diagnosed as having type 2 diabetes mellitus base on CPG Malaysia Clinical Practice Guidelines (CPG) for Type 2 Diabetes Mellitus (T2DM) 6th edition 2020.\n3. On oral hypoglycaemic agent(s)\n4. HbA1c 7- 10 % (result 3 months from the date of recruitment)\n5. Agree not to take other beverages, herbal or nutritional supplements for the duration of the study.\n\nExclusion Criteria:\n\n1. Severe diabetic complication(s) including end-stage renal disease and proliferative retinopathy.\n2. Pregnancy or plan to get pregnant during the study period\n3. Newly diagnosed diabetic less than 3 months from the date of recruitment\n4. Currently involve in any weight loss program\n5. Currently consuming any meal replacement product\n6. Patients with chronic kidney disease with eGFR ≤ 25 ml\u002Fmin.\n7. Patients with advanced liver disease, such as non-alcoholic steatohepatitis (NASH) with significant fibrosis (e.g., liver stiffness measurement \\> 9.5 kPa by FibroScan) or cirrhosis.\n8. Patients with significantly elevated liver enzymes (e.g., ALT or AST ≥ 3 times the upper limit of normal), which may indicate more severe liver damage.","ALL","30 Years","65 Years",{"count":89,"type":90},108,"ESTIMATED","INTERVENTIONAL",[93],"NA","To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes.\n\nMethodology:\n\nThis is an open-label, prospective, randomized control trial study. Study duration. August 2023 - March 2026. Study location. This study will be conducted at the Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia.\n\nSource Reference :\n\nPeople with type 2 diabetes mellitus attending the Hospital Universiti Sains Malaysia.\n\nStudy source population :\n\nPeople with type 2 diabetes mellitus attended Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia during the study period.",[96],"Diabetes Mellitus, Type 2","2025-03-02",{"date":99,"type":100},"2025-03-06","ACTUAL",{"date":102,"type":100},"2024-11-01",{"date":104,"type":90},"2026-03",{"name":5,"class":6},1]